Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 26 Sarcoma 16 Neoplasm Metastasis 12 Carcinoma, Non-Small-Cell Lung 9 Ovarian Neoplasms 8 Breast Neoplasms 8 Recurrence 6 Neoplasms 5 Melanoma 4 Liposarcoma 4 Leiomyosarcoma 4 Glioblastoma 4 Fallopian Tube Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Neuroendocrine Tumors 3 Lung Neoplasms 3 Kidney Neoplasms 3 Hemangiosarcoma 3 Gastrointestinal Stromal Tumors 3 Thyroid Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Sarcoma, Synovial 2 Sarcoma, Alveolar Soft Part 2 Rhabdomyosarcoma 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Gliosarcoma 2

Interventions

vandetanib 1 pazopanib 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × GIST × pazopanib × Clear all

NCT01323400 2016-02-25

PAZOGIST

Centre Leon Berard

Phase 2 Completed

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡